WAYLIVRA 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IAIN/0023 
A.1 - Administrative change - Change in the name 
08/11/2022 
and/or address of the MAH 
amended 
on 
SmPC, 
Labelling and 
PL 
II/0017/G 
This was an application for a group of variations. 
07/07/2022 
SmPC, 
Update of sections 4.8 and 5.1 of the SmPC to include data 
Labelling and 
from final results of study ISIS 304801 CS7 ('a multicentre 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
C.I.4: Update of sections 4.8 and 5.1 of the SmPC 
based on the final results from study (ISIS 304801 
CS7), a multicentre open label extension study of 
Volanesorsen administered subcutaneously to 
patients with Familial Chylomicronemia Syndrome. 
The Package Leaflet has been updated accordingly. 
The RMP version 2.2 has also been submitted. 
In addition, the MAH took the opportunity to 
implement editorial changes to the PI in order to 
align with the QRD template and to introduce minor 
linguistic update to Annex III of the product 
information to support product launch.  
C.I.11b. for RMP: Submission of an updated RMP 
version 2.2 based on the clinical study report 
addendum: A randomized, double blind, placebo 
controlled Phase 3 study of ISIS 304801 
administered subcutaneously to patients with 
Familial Chylomicronemia Syndrome (ISIS 304801 
CS6 (APPROACH).   
C.I.11b. for RMP: Submission of an updated RMP 
version 2.2 in order to update section V.2 Additional 
Risk Minimisation Measures in the RMP to reflect a 
change in the distribution methodology of the 
educational materials (from a centralised model to a 
localised model of distribution) and to clarify what is 
meant by the prescriber kit. 
C.I.13: Submission of the final report from study 
ISIS 304801 (CS17). This is a Phase 2/3 double 
blind, randomized, placebo controlled study, with an 
PL 
open label extension study of Volanesorsen administered 
subcutaneously to patients with Familial Chylomicronemia 
Syndrome'). The Package Leaflet and RMP have been 
updated accordingly. The MAH took the opportunity to 
make some editorial changes and bring the PI in line with 
the latest QRD template. 
Page 2/7 
 
 
 
 
 
 
 
 
open label extension of ISIS 304801 administered 
subcutaneously to patients with familial partial 
lipodystrophy. The RMP version 2.2 has also been 
submitted. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/10762
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
/202111 
volanesorsen 
IB/0020 
B.I.a.2.z - Changes in the manufacturing process of 
31/03/2022 
n/a 
the AS - Other variation 
IA/0019/G 
This was an application for a group of variations. 
21/03/2022 
n/a 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
R/0016 
Renewal of the marketing authorisation. 
16/12/2021 
14/02/2022 
PSUSA/10762
Periodic Safety Update EU Single assessment - 
02/12/2021 
n/a 
PRAC Recommendation - maintenance 
/202105 
volanesorsen 
IB/0015 
C.I.z - Changes (Safety/Efficacy) of Human and 
12/10/2021 
14/02/2022 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IB/0014 
B.II.z - Quality change - Finished product - Other 
17/09/2021 
n/a 
variation 
PSUSA/10762
Periodic Safety Update EU Single assessment - 
10/06/2021 
n/a 
PRAC Recommendation - maintenance 
/202011 
volanesorsen 
IB/0011/G 
This was an application for a group of variations. 
25/05/2021 
14/02/2022 
SmPC, 
The Product Information includes the following updates:  
Labelling and 
- To include the ATC Code in Section 5.1 of the Summary of 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
PL 
Product Characteristics (SmPC). 
- To change the shelf-life from '4 years' to '5 years' in 
section 6.3 of the SmPC. 
- To introduce editorial changes throughout the product 
information. 
R/0009 
Renewal of the marketing authorisation. 
10/12/2020 
04/02/2021 
The CHMP, having reviewed the available information on 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for WAYLIVRA, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
PSUSA/10762
Periodic Safety Update EU Single assessment - 
26/11/2020 
n/a 
PRAC Recommendation - maintenance 
/202005 
volanesorsen 
IA/0008/G 
This was an application for a group of variations. 
12/10/2020 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.d.1.c - Stability of AS - Change in the re-test 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
period/storage period or storage conditions - Change 
to an approved stability protocol 
B.I.d.1.c - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Change 
to an approved stability protocol 
IB/0006 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
12/06/2020 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
PSUSA/10762
Periodic Safety Update EU Single assessment - 
11/06/2020 
n/a 
PRAC Recommendation - maintenance 
/201911 
volanesorsen 
IB/0005 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
24/04/2020 
04/02/2021 
SmPC and PL 
life of the finished product - As packaged for sale 
(supported by real time data) 
R/0003 
Renewal of the marketing authorisation. 
30/01/2020 
16/03/2020 
The CHMP, having reviewed the available information on 
IB/0002 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
18/07/2019 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for WAYLIVRA, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
18/07/2019 
16/03/2020 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 7/7 
 
 
 
 
 
 
 
 
 
